等待开盘 11-17 09:30:00 美东时间
-0.430
-1.25%
11月13日,Maze Therapeutics(MAZE)收跌1.74%,报36.09美元,成交额1633.11万美元,市值19.74亿美元。 行情数据 •...
11-13 06:31
今日重点评级关注:韦德布什:维持Cullinan Therapeutics"跑赢大市"评级,目标价从42美元升至44美元;HC Wainwright & Co.:维持WhiteFiber"买入"评级,目标价从34美元升至36美元
11-12 19:19
今日重点评级关注:花旗:维持Faeth Therapeutics"买入"评级,目标价从55美元升至60美元;HC Wainwright & Co.:维持Ocular Therapeutix"买入"评级,目标价从25美元升至28美元
11-11 10:50
Wedbush analyst Laura Chico maintains Maze Therapeutics (NASDAQ:MAZE) with a Outperform and raises the price target from $48 to $49.
11-10 23:15
Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.79) per share which missed the analyst consensus estimate of $(0.77) by 2.6 percent. This is a 19.7 percent decrease over losses of $(0.66) per share from the same period last year.
11-10 05:41
Maze Therapeutics reported Q3 2026 financial results, highlighting $477M in cash and strong clinical progress. Enrollment completed for Phase 2 HORIZON trial of MZE829, with data expected in early 2027. MZE782's Phase 2 CIPheR trial in PKU is ongoing, with topline data anticipated in 2027, and a Phase 2 CKD trial planned for H1 2027. The company also announced new board appointments and reported a net loss of $48M for the quarter.
11-09 21:05
11月5日,Maze Therapeutics(MAZE)收涨3.5%,报33.38美元,成交额1777.14万美元,市值18.5亿美元。 行情数据 • 开盘价...
11-05 06:29
Maze Therapeutics, Inc. announced that its CEO, Jason Coloma, Ph.D., will participate in three investor conferences in November and December 2026. The events include the Guggenheim Healthcare Innovation Conference on November 10, the Jefferies Global Healthcare Conference in London on November 17, and the Evercore Healthcare Conference on December 1. Live webcasts will be available on the company's website and archived for 60 days. Maze Therapeut...
11-03 12:00
10月29日,Maze Therapeutics(MAZE)收涨0.13%,报31.73美元,成交额1237.52万美元,市值17.63亿美元。 行情数据 •...
10-29 05:30
10月27日,Maze Therapeutics(MAZE)收涨0.19%,报31.07美元,成交额1339.52万美元,市值17.26亿美元。 行情数据 •...
10-27 05:31